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Objective
To review the efficacy and safety of frovatriptan (F) vs.
rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in
women with menstrually related migraine (IHS criteria)
through a pooled analysis of three individual studies.
Methods
Subjects with a history of migraine with or without aura
were randomized to F 2.5 mg or R 10 mg (study 1), F or Z
2.5 mg (study 2), and F or A 12.5 mg (study 3). The
studies had an identical multicenter, randomized, double
blind, cross-over design. After treating 3 episodes of
migraine in no more than 3 months with the first treat-
ment, patients had to switch to the next treatment for
other 3 months.
Results
346 subjects formed the main study intention-to-treat
population; 280 of them were of a female gender (81%) and
236 in the fertile age. A total of 187 out of the 236 eligible
women (79%) treated at least one episode of menstrual
migraine with both medications and were thus included in
the present subgroup analysis. Rate of pain free at 2, 4 and
24h was 23%, 52% and 67% with F and 30%, 61% and 66%
with comparators (p=NS). Pain relief episodes at 2, 4 and
24h were 37%, 60% and 66% for F and 43%, 55% and 61%
for comparators (p=NS). Rate of recurrence was signifi-
cantly (p<0.05) lower under F either at 24h (11% vs. 24%
comparators) or at 48h (15% vs. 26% comparators).
Number of menstrual migraine attacks associated with
drug-related adverse events was equally low (p=NS)
between F (5%) and comparators (4%).
Conclusions
According to our analysis of individual studies F is as
effective as other triptans in the immediate treatment of
menstrual migraine attacks, but exhibits a more sus-
tained effect.
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